Close

Clinical Trials

Avaxia treats first patient in ulcerative colitis drug study

Avaxia Biologics has treated the first patient in a Phase1b clinical study using AVX drug dosage, designed for the treatment of ulcerative colitis. The gut-targeted anti-TNF antibody drug is injected into the body to...

CSL Behring begins pediatric Phase III hemophilia B study of rIX-FP

CSL Behring has commenced the patient enrollment in pivotal pediatric Phase III hemophilia B study of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). The study is designed to assess rIX-FP's...

GlycoMimetics completes enrollment in Phase 2 study of GMI-1070

Clinical-stage biotechnology company GlycoMimetics has completed patient enrollment for the Phase 2 sickle cell disease study evaluating GMI-1070. Hospitalized sickle cell disease patients experiencing vaso-occlusive crisis were examined for the efficacy, safety and pharmacokinetics...

Kiadis Pharma raises fund for Phase II study of ATIR

Kiadis Pharma has raised EUR10m in a financing round to conduct Phase II study of a cell based medicinal product candidate, ATIR, and to prepare a Phase II/III study. ATIR Phase II study is...

Pfizer Phase 3 fibromyalgia study of pregabalin meets primary endpoint

Pfizer Phase III study of pregabalin controlled-release (CR) formulation has met primary endpoint of time to loss of therapeutic response (LTR), in fibromyalgia patients. The primary endpoint of the placebo-controlled, multi-center study was achieved...

Idera completes patient enrollment in Phase 2 trial of IMO-3100

Idera Pharmaceuticals has concluded enrolling patients in double-blind, placebo-controlled Phase 2 trial assessing IMO-3100 in psoriasis patients. The study randomized 44 patients suffering from moderate to severe plaque psoriasis with IMO-3100 at 0.16mg/kg or...

Novavax pandemic influenza vaccine meets endpoints in two Phase 1 trials

Novavax A/H5N1 avian influenza vaccine candidate has met safety and immunogenicity endpoints in two Phase 1 clinical trials. The trials achieved the primary objectives by displaying the safety and immunogenicity of different doses of...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป